ARA 290: What It Is, How It Works, and What the Research Actually Shows

What Exactly Is ARA 290?

ARA 290, also called cibinetide, is a short synthetic peptide containing 11 amino acids. It is engineered from a helix-B surface peptide region of erythropoietin (EPO), the glycoprotein hormone that ordinarily drives red blood cell production. By isolating this specific surface sequence, researchers created a molecule that binds the innate repair receptor (a heterodimer of the EPO receptor and the beta-common receptor, also called CD131) without triggering erythropoiesis or the thromboembolic risks associated with full EPO administration.

The innate repair receptor is expressed on macrophages, dendritic cells, neurons, and pancreatic beta cells, which explains why ARA 290 has been studied across such different disease categories: peripheral neuropathy, type 2 diabetes, sarcoidosis, and inflammatory conditions. Early preclinical work at Araim Pharmaceuticals (hence "ARA") established that the peptide reduces pro-inflammatory cytokines including TNF-alpha and IL-6 in rodent models [1].

The distinction between the classic EPO receptor homodimer and the innate repair receptor heterodimer is not merely pharmacological trivia. It is the structural reason ARA 290 can be dosed without a complete blood count or hematocrit monitoring protocol, unlike recombinant EPO itself. Full EPO therapy at supraphysiologic doses raises hemoglobin and increases stroke or thrombosis risk, a concern that famously led the FDA to mandate a REMS program for ESAs in cancer patients [2].

The Leiden University Randomized Controlled Trial: Core Evidence

The most-cited clinical evidence for ARA 290 comes from a double-blind, placebo-controlled trial conducted at Leiden University Medical Center and published in 2015 in Molecular Medicine (N=55 patients with sarcoidosis-associated small fiber neuropathy) [3].

Participants received either 4 mg ARA 290 subcutaneously once daily for 28 days or matching placebo. The primary endpoints were patient-reported neuropathic symptoms on the Small Fiber Neuropathy Symptoms Inventory Questionnaire (SFN-SIQ) and corneal confocal microscopy to measure intraepidermal nerve fiber regeneration.

Key findings included:

• Neuropathic symptom scores fell significantly in the ARA 290 group vs. placebo (P<0.05 on SFN-SIQ total score).
• Corneal nerve branch density increased by approximately +0.5 branches/mm² in the treatment arm, while the placebo arm lost roughly 0.3 branches/mm² over the same interval.
• Metabolic parameters improved: fasting glucose decreased and insulin sensitivity indices trended upward in treated patients who also had impaired glucose regulation.
• Adverse events were mild and largely limited to injection-site erythema.

The trial's authors noted: "ARA 290 treatment was associated with improvement in neuropathic symptoms and signs and with improvement in metabolic parameters, supporting the use of ARA 290 as a disease-modifying therapy in patients with sarcoidosis-associated SFN." [3]

That language is specific. It says "associated with," not "cures" or "definitively treats." The N=55 sample is also modest. Replication in a larger, multi-center phase III trial has not yet been published as of early 2025, which is the primary reason the peptide remains investigational rather than approved.

A separate open-label extension study from the same Leiden group (N=18, 2016) examined 4 mg daily over 12 weeks and showed sustained corneal nerve fiber recovery, but open-label data without a concurrent control arm carries lower evidentiary weight [4].

Mechanism: The Innate Repair Receptor Pathway

Binding the beta-common receptor / EPO receptor heterodimer triggers downstream signaling through Jak2, PI3K/Akt, and NF-kB suppression pathways. The net effect in peripheral neurons is reduced apoptosis, decreased neuroinflammation, and promotion of neurotrophic signaling.

This is not a theoretical pathway. EPO's neuroprotective effects in stroke models were documented as early as 2002 [5], but full-length EPO could not be used clinically for neuroprotection because of erythropoiesis and vascular risks at the doses required. ARA 290 separates the tissue-protective signal from the hematopoietic signal, at least in current preclinical and phase II data.

In macrophages, ARA 290 shifts polarization away from the M1 pro-inflammatory phenotype toward M2 tissue-repair phenotype. A 2014 study in Journal of Neuroinflammation demonstrated that 10 nM ARA 290 reduced LPS-stimulated TNF-alpha secretion by approximately 60% in human monocyte-derived macrophages [6]. That kind of magnitude is meaningful in a cell-culture context, though translation to in-vivo dosing is always imperfect.

ARA 290 and Metabolic Health: The Diabetes Angle

Pancreatic beta cells express CD131, which is why several investigators have explored ARA 290 for type 2 diabetes and prediabetes.

A proof-of-concept open-label study (N=20 patients with type 2 diabetes, Leiden group, 2013) administered 4 mg ARA 290 daily for 4 weeks. HbA1c dropped by 0.4 percentage points and fasting insulin sensitivity improved on HOMA-IR, though no placebo group was included [7]. That is a small effect on HbA1c and would not come close to matching the 1.5 to 2.0% HbA1c reductions seen with GLP-1 receptor agonists like semaglutide in the SUSTAIN-6 trial (N=3,297) [8]. ARA 290 is not being positioned as a diabetes monotherapy; rather, its potential role may be in peripheral neuropathy that accompanies diabetes.

HealthRX Clinical Framework: When ARA 290 Might Be a Relevant Conversation

Clinicians reviewing this evidence might find ARA 290 most relevant for patients who have:

1. Confirmed small fiber neuropathy (skin punch biopsy with reduced intraepidermal nerve fiber density, below 5th percentile for age/sex per normative data).
2. An inflammatory or autoimmune etiology, particularly sarcoidosis, where the innate repair receptor pathway is most plausibly active.
3. Suboptimal response to standard neuropathic agents (pregabalin, duloxetine, amitriptyline) at adequate doses.
4. No contraindication to subcutaneous peptide therapy and access to a monitoring clinician.

This framework is not a treatment protocol. Any peptide use outside an IRB-approved trial requires individualized physician judgment.

Related Peptides: Epitalon, MOTS-c, SS-31, and Humanin

Because searches for ARA 290 frequently appear alongside these four peptides, a brief, evidence-grounded comparison serves the reader.

Epitalon

Epitalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide modeled on epithalamin, a natural pineal gland extract studied by the late Russian gerontologist Vladimir Khavinson. Most published data come from Russian-language journals and from Khavinson's own group, a fact that warrants methodological caution. The strongest mechanistic claim is telomerase activation: a 2003 paper in Neuro Endocrinology Letters reported that epitalon increased telomere length in cultured human somatic cells [9]. Whether that translates to clinically meaningful longevity outcomes in humans is unknown; no phase III RCT exists. The peptide also appears to regulate melatonin secretion through pineal stimulation in animal models. Epitalon is not FDA-approved and is not on the FDA 503B bulk substance nomination lists.

MOTS-c

MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded by mitochondrial DNA and discovered in 2015 by Cohen and colleagues at the USC Davis School of Gerontology [10]. It acts as a metabolic regulator by activating AMPK, suppressing the folate cycle, and improving insulin sensitivity in skeletal muscle. A 2021 study in Nature Communications (N=mouse cohort, N=32 elderly humans as an observational arm) found that circulating MOTS-c levels decline with age and that exogenous MOTS-c improved physical performance in aged mice [11]. Human interventional data remain sparse. Researchers at the National Institute on Aging have described MOTS-c as "an exercise mimetic peptide," which is accurate for preclinical models but still speculative for clinical practice.

SS-31

SS-31 (elamipretide, D-Arg-Dmt-Lys-Phe-NH2) is a mitochondria-targeting tetrapeptide that concentrates at the inner mitochondrial membrane by binding cardiolipin. Its mechanism is oxidative phosphorylation optimization: by stabilizing cardiolipin-cytochrome c interactions, SS-31 reduces electron leak and reactive oxygen species production. The PROGRESS-HF trial (NCT02914665) tested intravenous elamipretide in heart failure with preserved ejection fraction (HFpEF) and did not meet its primary endpoint of 6-minute walk distance improvement, though secondary quality-of-life measures showed modest benefit [12]. A Barth syndrome trial (a rare mitochondrial cardiomyopathy) showed more promising results. SS-31 is the most clinically advanced mitochondrial peptide currently in trials.

Humanin

Humanin is a 21-amino-acid peptide originally identified in 2001 from the surviving neuronal tissue of an Alzheimer's disease brain [13]. It signals through receptors including gp130 and FPRL1 and appears to suppress neuronal apoptosis. Serum humanin levels are lower in individuals with type 2 diabetes and coronary artery disease relative to healthy controls in cross-sectional data [14]. No randomized human interventional trial has been completed. Its interest in longevity research partly derives from the observation that circulating humanin levels in centenarians' offspring are higher than in age-matched controls from the general population, per a 2016 study in Aging (N=134 subjects) [15].

Regulatory Status: What the FDA's 2023-2024 Actions Mean for These Peptides

In 2023 and early 2024, the FDA moved to restrict compounding pharmacy access to several peptides by placing them on lists of bulk drug substances that do not qualify for compounding under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act. The agency's position is that peptides with insufficient clinical evidence, unresolved safety data, or that are essentially copies of approved drugs should not be available through compounding channels [16].

ARA 290 is not on any FDA 503A or 503B approved bulk substance list as of early 2025. That means a licensed 503A compounding pharmacy cannot legally compound it for individual patients without an FDA-issued investigational new drug (IND) exception. It remains accessible only within clinical trials.

Epitalon, MOTS-c, SS-31, and humanin occupy a similar gray zone. SS-31/elamipretide is furthest along the IND pathway (Stealth BioTherapeutics held an IND), but the company restructured following the PROGRESS-HF outcome. Patients who obtained these peptides through compounding pharmacies prior to 2023 should be aware that ongoing supply through that channel may not be legally compliant and that product quality without USP-grade independent testing is unverifiable.

The Endocrine Society's 2023 clinical practice guidance on compounded hormones and peptides states: "Patients should be counseled that compounded preparations have not undergone FDA review for safety, efficacy, or manufacturing quality, and their use outside of a clinical trial carries inherent uncertainty." [17]

Dosing and Administration: What Trial Protocols Used

No FDA-approved dosing regimen exists for ARA 290. Published trial protocols used:

• 4 mg subcutaneous injection once daily for 28 days (Leiden RCT, 2015) [3].
• 4 mg subcutaneous injection once daily for 12 weeks (Leiden open-label extension, 2016) [4].

Higher doses have not been formally tested in published peer-reviewed human trials. Preclinical rodent data used doses of 30-60 mcg/kg, roughly equivalent to 2-5 mg in a 70 kg human, consistent with the clinical trial range.

The half-life of ARA 290 after subcutaneous injection is approximately 2-4 hours based on pharmacokinetic data from early phase I work. There is no published data on oral bioavailability; the peptide is expected to undergo significant gastrointestinal degradation, like most short peptides without modification.

Safety Profile: What the Trials Reported

Across published ARA 290 trials, the adverse event profile has been mild:

• Injection-site erythema and mild local reactions were the most frequent reports.
• No hematologic changes (hemoglobin, hematocrit, platelet counts) were observed, consistent with the non-erythropoietic mechanism.
• No thromboembolic events were reported in the combined N=55 + N=18 Leiden cohorts.
• Liver enzymes and kidney function remained within normal limits across reported follow-up periods.

That reassuring profile must be interpreted with appropriate context: aggregate exposure across all published trials is under 100 patients. Rare adverse events at a frequency of 1 in 500 would not be detectable in this sample size. Long-term safety data beyond 12 weeks do not exist in peer-reviewed literature.

Where ARA 290 Research Stands Now

As of early 2025, Araim Pharmaceuticals has not published results from a phase III confirmatory trial. ClinicalTrials.gov shows historical registrations for ARA 290 in sarcoidosis-associated SFN, but no actively recruiting large-scale trial appears on the registry.

The 2015 Leiden RCT remains the key dataset. Without phase III replication, regulatory approval pathways for the United States or European Union are not open. Academic interest in the molecule continues, particularly in sarcoidosis research centers in the Netherlands and Scandinavia, where small fiber neuropathy associated with sarcoidosis is a recognized clinical problem affecting approximately 40% of sarcoidosis patients with neurological involvement [3].

Patients with sarcoidosis who have confirmed SFN and are considering ARA 290 should ask their neurologist or sarcoidosis specialist whether any active investigator-initiated trials are enrolling. That is the only legally and scientifically sound access pathway in the United States today.